TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06654089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Emergen-C Core Super Orange Powder
Description: A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A study product identical to the test product without active ingredients.
Study: NCT06158698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
Study: NCT06296550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dulce Digital Text Messaging Intervention
Description: Text-based education support program:~* Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months.~* Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading.

Intervention type: OTHER
Group type: OTHER
Intervention: Dulce Digital Text Messaging Intervention
Description: Text-based education support program:~* Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months.~* Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM Device
Description: Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
Study: NCT06233279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Charge-Balanced, Symmetric Nerve Stimulation
Description: Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
Study: NCT06663722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered intravenously (IV) at a dose of 0.3 mg/kg, beginning as a pre-phase dose two weeks prior to initiation of Extracorporeal Photopheresis (ECP) therapy. Thereafter, Axatilimab will be administered with a frequency of one treatment session bi-weekly during each treatment cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Mandatory ECP therapy will be administered at a frequency of two treatment sessions per week during Cycles 1 through 3, two treatment bi-weekly during Cycles 4 through 6, and two treatments during week 1 of Cycle 7.~Optional ECP therapy will be administered at a frequency of two treatment sessions during weeks 2 and 4 of Cycles 4 through 6, when mandatory ECP is not administered. Optional ECP therapy will also be administered as two treatment sessions during week 3 of Cycle 7.~After Cycle 7, participants may receive ECP therapy only at the Investigator's discretion for a maximum Treatment Period of 12 months.
Study: NCT06658197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
Study: NCT06664918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral food challenge (OFC)
Description: oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral food challenge (OFC)
Description: oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)
Study: NCT06602232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 will be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 will be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 will be administered via IV infusion.
Study: NCT06602466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste
Description: 0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: Commercial toothpaste containing 1450 ppm fluoride.
Study: NCT05560854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered prolonged exposure
Description: Internet delivered prolonged exposure for ten weeks with therapist support.
Study: NCT06668376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leg Sleeve
Description: Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
Study: NCT06252779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma therapy equipment
Description: The host of this product contains a high-voltage generator that can generate high-voltage electrical energy and deliver it to the treatment head. The air supply mechanism sends air to the ionization chamber inside the treatment head, which is ionized under the action of high-voltage electricity to generate thermal plasma, forming a particle flow mainly composed of active nitric oxide (pNO), which is then sprayed out from the nozzle of the treatment head to the target tissue of the human body. PNO particles can alter skin permeability, allowing them to act on specific parts of the body after transdermal absorption on the surface of the body.The patient will receive 14 days of treatment, with 20 minutes per day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fake therapeutic device
Description: False stimuli with the same appearance and pattern as Plasma therapy equipment.The patient will receive 14 days of treatment, with 20 minutes per day.
Study: NCT06054906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab+metronomic PLOF
Description: Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles
Study: NCT06674733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox administration
Description: Treatment for bruxism

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: treatment for stress-bruxism

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation
Description: Before the procedure, and at 1 month and 3 months after the procedure, the Fonseca questionnaire, symptom assessment questionnaire, and Basic Scale on Insomnia Complaint and Quality of Sleep (BaSIQS) will be administered. At the 1st month and 3rd month, Subject Global Aesthetic Improvement Scale (GAIS), and satisfaction questionnaire will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation
Description: Before the procedure, and at 1 month and 3 months after the procedure, the Fonseca questionnaire, symptom assessment questionnaire, and Basic Scale on Insomnia Complaint and Quality of Sleep (BaSIQS) will be administered. At the 1st month and 3rd month, Subject Global Aesthetic Improvement Scale (GAIS), and satisfaction questionnaire will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging Time
Description: Panoramic radiographs will be taken before the procedure and three months after the procedure. Ultrasonography examination will be performed before the procedure, one month after, and three months after the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging Time
Description: Panoramic radiographs will be taken before the procedure and three months after the procedure. Ultrasonography examination will be performed before the procedure, one month after, and three months after the procedure.
Study: NCT06624085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV obinutuzumab pretreatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
Study: NCT06684119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography positive end-expiratory pressure titration
Description: A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.
Study: NCT05648110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD5156 (Parent study Sentinel Safety Cohort)
Description: 600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD5156 (Parent study Sentinel Safety Cohort)
Description: 600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD5156 (Parent study Sentinel Safety Cohort)
Description: 600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD5156 (Parent study Sentinel Safety Cohort)
Description: 600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Parent study Sentinel Safety Cohort)
Description: single dose of Placebo (3 mL + 2 mL) IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Parent study Sentinel Safety Cohort)
Description: single dose of Placebo (3 mL + 2 mL) IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Parent study Sentinel Safety Cohort)
Description: single dose of Placebo (3 mL + 2 mL) IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Parent study Sentinel Safety Cohort)
Description: single dose of Placebo (3 mL + 2 mL) IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Parent study Sentinel Safety Cohort)
Description: single dose of Placebo (3 mL + 2 mL) IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EVUSHELD™ (Parent study Main Cohort)
Description: 600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Parent study Main Cohort)
Description: 300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Parent study Main Cohort)
Description: Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Sub-study)
Description: Single dose of 1200 mg IV at Visit 1 Day 1
Study: NCT06221241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000623
Description: tablets for oral administration.
Study: NCT05648110

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD7442 - EVUSHELD™ (Sub-study)
Description: Single dose 300 mg IM administered on Visit 1 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Description: Single dose of AZD7442 (EVUSHELD™) 300 mg IM
Study: NCT06695195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: 25 mg capsule twice daily
Study: NCT06221241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matched to JMKX000623 and Pregabalin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched to JMKX000623 and Pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matched to JMKX000623 and Pregabalin
Study: NCT06695195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg capsule twice daily
Study: NCT06723678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two distally inclined 45-degree angle posterior implants
Description: During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two distally inclined 30-degree angle posterior implants
Description: During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients
Study: NCT06723808

Intervention type: OTHER
Intervention: Leisure-Time Physical Activity and Occupational Physical Activity
Description: This study does not involve a specific intervention but explores the relationship between leisure-time physical activity (LTPA) and occupational physical activity (OPA) in university staff, with a focus on work ability, musculoskeletal disorders, and quality of life.
Study: NCT06733350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Prostate
Description: Undergo prostate biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo prostate biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Prostate
Description: Undergo prostate biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo standard AS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo standard AS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo standard AS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04955314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PA vertebral mobilization
Description: A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PA vertebral mobilization
Description: A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist
Study: NCT04981808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Telemonitoring of CGM and insulin pen data
Study: NCT04797702

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Glumetinib combined with Toripalimab
Description: Ib：All enrolled subjects received Glumetinib combined with Toripalimab on a 21-day cycle, starting with 200mg/ day continuous Glumetinib and 240mg/ 3 weeks Toripalimab.~II：The SMC will determine the dose group for the Phase II study based on the safety and initial efficacy data of the Phase Ib subjects. Approximately 62 evaluable subjects will be enrolled in the study to receive the recommended dose of Glumetinib once daily and continuous treatment with Toripalimab 240mg every 3 weeks.
Study: NCT06733350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Testosterone
Description: Given via injection, gel, lotion, or transdermal patch
Study: NCT06733064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of vitamin D3
Description: Supplementation of vitamin d3 at a dose of 4000 iu / day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegetable oil as a placebo
Study: NCT06477562

Intervention type: OTHER
Intervention: Endoscopy
Description: surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
Study: NCT03037814

Intervention type: DEVICE
Group type: OTHER
Intervention: Compomer
Description: Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.

Intervention type: DEVICE
Group type: OTHER
Intervention: Compomer
Description: Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.

Intervention type: DEVICE
Group type: OTHER
Intervention: Compomer
Description: Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.

Intervention type: DEVICE
Group type: OTHER
Intervention: RMGIC
Description: Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
Study: NCT06733103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Cognitive Behavioural Therapy
Description: This is the only intervention in this clinical (feasibility) study
Study: NCT06732076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based education
Description: web based education
Study: NCT03037814

Intervention type: DEVICE
Group type: OTHER
Intervention: RMGIC
Description: Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.

Intervention type: DEVICE
Group type: OTHER
Intervention: RMGIC
Description: Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.

Intervention type: DEVICE
Group type: OTHER
Intervention: Giomer
Description: Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.